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High-throughput phenotypic screens have re-emerged as screening tools in antibiotic discovery. 
The advent of such technologies has rapidly accelerated the identification of ‘hit’ compounds. A pre-
requisite to medicinal chemistry optimisation programmes required to improve the drug-like properties 
of a ‘hit’ molecule is identification of its mode of action. Herein, we have combined phenotypic 
screening with a biased target-specific screen. The inosine monophosphate dehydrogenase (IMPDH) 
protein GuaB2 has been identified as a drugable target in Mycobacterium tuberculosis, however 
previously identified compounds lack the desired characteristics necessary for further development into 
lead-like molecules. This study has identified 7 new chemical series from a high-throughput resistance-
based phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2. Hit compounds 
were identified in a single shot high-throughput screen, validated by dose response and subjected to 
further biochemical analysis. The compounds were also assessed using molecular docking experiments, 
providing a platform for their further optimisation using medicinal chemistry. This work demonstrates 
the versatility and potential of GuaB2 as an anti-tubercular drug target.
Tuberculosis (TB), the disease caused by the pathogen Mycobacterium tuberculosis (Mtb), affects 9 million peo-
ple each year, and is attributed to over 1.5 million deaths, and is reported to be the biggest killer worldwide 
due to a single infectious agent alongside HIV/AIDS1. This, coupled with the emergence of multi-drug and 
extensively-drug resistant (MDR and XDR) Mtb infections, which infects approximately 0.5 million people each 
year, has prompted efforts to produce new and safe antibiotics that do not interfere with current anti-retroviral 
drugs in HIV/TB co-infected individuals2–4. The current WHO-recommended directly observed treatment 
short-course (DOTS) regimen for drug-susceptible infections of Mtb requires further refinement due to the 
lengthy duration of treatment and considerable pill burden5.
Recent innovations in high-throughput screening (HTS) have accelerated drug discovery, making it possible 
to test millions of compounds for antimicrobial activity in weeks rather than years. As a result many new mol-
ecules have been discovered by whole-cell phenotypic screening campaigns and published due to their potent 
inhibitory activity. Indeed, the first new TB drug, Bedaquiline (brand name SirturoTM, formerly TMC207) to 
receive FDA approval since 1971, was first recognized as a potential anti-TB compound in a whole-cell pheno-
typic HTS campaign. SirturoTM, a member of the diarylquinoline (DARQ) family, was identified as an inhibitor of 
both drug-sensitive and drug-resistant Mtb6,7. During clinical trials, it was found that many patients experienced 
drug-induced QTcF prolongation (an extended time between depolarization and repolarization of the ventricles) 
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as a side-effect of SirturoTM. Nevertheless, the drug was approved for use on a case-by-case basis in the treatment 
of MDR-TB8. Despite the novelty of phenotypic ‘hits’, the majority of compounds are unlikely to progress as leads 
or drug candidates due to their undesirable molecular structure, promiscuous mode of action and their frequent 
appearance in screening campaigns. Some of these molecules are now considered artefacts of HTS, and have 
recently received the designation as PAINS (Pan-Assay InterferenNe compoundS), and filters are being employed 
to prevent time and money being invested on molecules of this type9.
Inosine monophosphate (IMP) is a metabolic precursor in the biosynthesis of the purine nucleotides adenine 
and guanine. Guanosine monophosphate (GMP) requires the synthesis of xanthosine monophosphate (XMP) 
from IMP by the inosine monophosphate dehydrogenase (IMPDH), of which there are three in Mtb, GuaB1 
(Rv1843c), GuaB2 (Rv3411c) and GuaB3 (Rv3410c)10,11. The rate limiting two-step catalysis of IMP to XMP con-
version by IMPDH requires nicotinamide adenine dinucleotide (NAD+) as a cofactor, which is first reduced 
to NADH by a dehydrogenation reaction, forming an intermediate covalent bond between IMPDH and XMP, 
followed by a hydrolysis reaction that breaks the covalent attachment and releases XMP12. GuaB2 is the only 
catalytically active and essential IMPDH shown by transposon site hybridization (TraSH) to be required for via-
bility of Mtb13,14. Inhibition of GuaB2 results in depletion in guanine nucleotides for DNA and RNA synthesis15,16. 
Biochemical characterisation of GuaB2 has been previously conducted and a series of diphenyl-urea (DPU) based 
inhibitors of Mtb were shown to inhibit Mtb GuaB2. An over-expresser based MIC shift analysis was conducted 
to validate the target in Mycobacterium smegmatis and a 16-fold increase in MIC (0.5–8 μ g.ml−1) was observed13. 
There are three distinct classes of IMPDH inhibitors, type I inhibitors are IMP or XMP analogues, type II inhib-
itors are NAD+/NADH analogues, whereas type III are muti-substrate inhibitors17. The aforementioned DPU 
compounds were designated as type III, along with a series of compounds identified in a screen of commercially 
available molecules which target mycobacterial GuaB2. In this instance, the lead molecule, 7759844, demon-
strated high potency with a Ki 0.603 μ M and MIC of 0.633 μ g.ml−1, however displayed toxicity in a chronic mouse 
model18. Several crystal structures of GuaB2 from Mtb have recently been determined in complex with sub-
strate, product and cofactors along with a number of new compounds with anti-mycobacterial activity19–21. This 
enhanced understanding of the biophysics of GuaB2 inhibition can be used for in silico drug discovery and for the 
assessment of newly discovered anti-mycobacterial compounds targeting GuaB2. Following a high-throughput 
resistance-based phenotypic screen using a GuaB2 over-expressing strain of M. bovis BCG, we present 7 new 
inhibitors of Mtb GuaB2, and their subsequent biochemical and in silico assessment. These diverse compounds 
contribute to a growing pool of GuaB2 inhibitors, laying a foundation for a future medicinal chemistry optimisa-
tion programmes and acceleration of GuaB2 as a future anti-tubercular drug target.
Results
Identification and in vitro validation of novel inhibitors of Mtb GuaB2. Here we present 7 novel 
inhibitory compounds targeting Mtb GuaB2. These compounds have been given the identifier JAGC_1 to 
JAGC_7, respectively. The chemical structures of each of these molecules are given in Fig. 1(a) and details of their 
chemical data are presented in Supplementary Table 1.
These new GuaB2 anti-mycobacterial compounds were discovered by a target-specific HTS using M. bovis 
BCG over-expressing the essential IMPDH, against a GSK 10,000 compound collection of known inhibitors of 
Mtb (the ‘TB Box’ set)22. A commercially available luciferase reporter assay was used to measure cell viability of 
each strain following 7 days of incubation with each of the ‘TB Box’ set at 1 and 10 μ M in a 1536-well format. Hits 
were identified based on shift in apparent inhibition (calculated as % inhibition of M. bovis BCG pMV261 (empty 
plasmid) minus % inhibition of M. bovis BCG pMV261-guaB2 [based upon duplicate data]), resulting in 256 
compounds that were further selected to be tested in a dose response manner.
Compounds were analysed using a serial dilution from 10 mM to 0.17 nM against M. bovis BCG pMV261 and 
M. bovis BCG pMV261-guaB2. The percentage inhibition at each concentration was used to determine the XC50 
(compound concentration required to inhibit cell viability by 50%) of each compound against the over-expresser 
and empty vector strains based on duplicate data. This resulted in the identification of 66 compounds with a sig-
nificant shift in XC50 (pXC50 ≥ 0.3), representing a 25.78% successful refinement from the initial HTS. The XC50 
data for M. bovis BCG pMV261 and M. bovis BCG pMV261-guaB2 against JAGC_1–7 is shown in Fig. 1(b). The 
pXC50 values for JAGC_1–7 are displayed in Table 1 along with the Z’ values for the dose response validation. 
The 66 dose response validated molecules were then subjected to a PAINS filter in order to remove compounds 
that are likely to represent promiscuous hits9. From this, 19 compounds were identified that displayed phenotypic 
resistance upon GuaB2 over-expression in M. bovis BCG when compared to an empty vector control strain. 
However, in order to rule out the potential of compound metabolism by M. bovis BCG, resulting in toxic adducts 
with specificity to Mtb GuaB2 (i.e. GuaB2 targeting pro-drugs), the 19 compounds were re-tested in a Mtb GuaB2 
in vitro biochemical assay18. The optimised DPU compound DPU-2 and fatty acid biosynthesis inhibitor isoni-
azid (INH) were used as positive and negative controls of Mtb GuaB2 inhibition, respectively. The results of the 
in vitro biochemical assay identified 7 compounds with mean inhibitory activity against GuaB2 ranging from 
26.5% (JAGC_2) to 12.3% (JAGC_6) inhibition, compared to the optimised DPU-2 compound that exhibited 
44.6% inhibition and INH which appeared to enhance GuaB2 activity (− 9% inhibition). The in vitro biochemical 
assay data is summarised in Fig. 1(c) and is detailed in Table 1.
In silico Binding of Compounds JAGC_1–7 and DPU-2 to Mtb GuaB2. We performed docking cal-
culations to assess the binding orientations of compounds JAGC_1–7 and to study their protein-ligand interac-
tions using the Internal Coordinate Mechanism (ICM) method developed by Molsoft L.L.C23. Molecular docking 
approaches are widely applied in drug discovery to provide information that facilitates structure-based drug dis-
covery and molecular modifications. The 4ZQP GuaB2-KP3 complex regenerated the crystal structure conforma-
tions of most ligands during cross-docking. Therefore, the structure was superior over the rest of the complexes 
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(PDB codes: 4ZQO and 4ZQN, 4ZQM) extracted from the PDBe, http://www.ebi.ac.uk/pdbe24. The seven com-
pounds, JAGC_1–7, and a previously documented optimised inhibitor of GuaB2, DPU-213 were docked into the 
NAD+ and IMP binding sites based on two crystal structures (4ZQP and 4ZQM). The structure, 4ZQP, is a com-
plex of Mtb GuaB2 with two ligands bound, IMP and an inhibitor KP3 occupying the NAD+ site, whereas 4ZQM 
shows GuaB2 co-crystallised with the product XMP and the co-factor NAD+. All compounds demonstrated 
Figure 1. (a) Newly identified anti-mycobacterial compounds that target the essential inosine monophosphate 
dehydrogenase, GuaB2 (JAGC_1–7). These molecules have been identified in a target-based HTS using M. bovis 
BCG over-expressing GuaB2 from Mtb. Chemical structures of the DPU compounds (DPU-1-3) are also shown 
(boxed)13. Details of the chemical data for JAGC_1–7 is provided in Supplementary Table 1. (b) Graph illustrating 
the difference in XC50 (compound concentration required to inhibit cell viability by 50%) of each compound 
against M. bovis BCG pMV261 and M. bovis BCG pMV261-guaB2. (c) Graph showing the percentage biochemical 
inhibition of GuaB2 by JAGC_1–7 respectively, with isoniazid (INH) and an optimized diphenyl urea compound 
(DPU-2), as respective negative and positive controls.
Z’ Value
Target Plate 1 Plate 2 Plate 3 Plate 4
GuaB2 0.74 0.76 0.74 0.74
GuaB2 EV 0.41 0.76 0.73 0.67
Compound ID pXC50 for Empty Vector
pXC50 Mean 
for GuaB2 Shift pIC50
% Biochemical 
Inhibition of Mtb GuaB2
SD of % Biochemical 
Inhibition of Mtb GuaB2
MIC (μM) 
H37Rv
JAGC_1 5.05 ≤ 4 1.05 23.09 0.51 > 80
JAGC_2 5.08 4.24 0.84 26.53 11.77 > 80
JAGC_3 4.99 ≤ 4 0.99 21.75 10.28 > 80
JAGC_4 4.64 ≤ 4 0.64 20.74 6.86 > 80
JAGC_5 5.36 4.42 0.94 20.62 6.45 > 100
JAGC_6 5.42 4.35 1.07 15.44 1.61 > 80
JAGC_7 5.38 5.01 0.37 12.25 7.45 50
DPU-2 44.6 4.21
INH − 8.88 2.64
Table 1. Z’ and pXC50 values for dose response validation of GuaB2 targeting compounds.
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higher affinities for the NAD+ site as shown by the highly negative ICM scores (Table 2). When compared to 
the affinity of the crystal structure ligand, KP3, two compounds JAGC_2 and JAGC_7 displayed higher binding 
affinity and all compounds had lower affinity for the IMP site compared to XMP.
The NAD+ binding site in Mtb GuaB2 stretches from the adenosine sub-site defined by N289, L291, V292 and 
G260 to the nicotinamide sub-site with the middle part of the molecule stretching over the inhibitor minimal 
structural moiety (IMSM)19. Occupation of the nicotinamide sub-site and interactions of small molecules with 
the purine ring of IMP have been found to be crucial for binding and protein inhibition. All seven compounds 
consist of at least one aromatic ring or cyclic sub-structure and their highest binding affinity conformations 
indicated that one ring occupied the nicotinamide sub-site resulting in π -stacking with the purine ring in IMP 
(Fig. 2). The molecular orientations in Fig. 2 gave the highest affinities for binding and their positions relative to 
IMP and NAD+ are shown. Compound JAGC_7 showed the highest Ligand Efficiency Index (LEI = 0.99) for the 
NAD+ site and for the IMP site (LEI = 0.64) (Table 2).
In silico Binding Mode of JAGC_7. Compound JAGC_7, (3-(1,2,3,-benzothiadiazol-5-yl)-1-(4-meth
ylcyclohexyl)-urea, has two ring systems and in the IMP site, the methylcyclohexane ring is placed either in 
the xanthosine or purine sub-site, whilst the benzothiadiazole ring orientates towards the IMP/XMP phosphate 
group sub-site (Fig. 3A). Similar to IMP and XMP, in this position the molecule is anchored by a dense network of 
hydrophobic interactions involving aromatic rings, cyclohexane and more than ten residues that include Tyr269, 
Met272 and Leu244 (Fig. 3B). This orientation places the cyclohexane in a stacking position with the π electrons 
in the nicotinamide end of NAD+ anchored the molecule resulting in even stronger carbon- π interactions. In 
addition, there are hydrogen bonds involving the nitrogen atoms in the thiadiazole ring with Ser187, and the Urea 
Oxygen with Ser56, which stabilise the other end of the molecule. The compound showed better binding affinity 
JAGC code MWt (g/mol) NAD+ site ICM Score NAD+ site LEI IMP site ICM Score IMP site LEI
JAGC_7 290.38 − 19.72 0.99 − 12.81 0.64
JAGC_2 372.85 − 22.76 0.88 − 1.41 0.05
JAGC_6 247.72 − 13.53 0.8 0.22 − 0.01
DPU_2 309.72 − 16.36 0.78 − 7.21 0.34
DPU_3 378.02 − 12.82 0.64 − 5.46 0.27
JAGC_1 362.43 − 16.96 0.63 8.73 − 0.32
JAGC_3 353.44 − 13.52 0.56 − 4.91 0.2
JAGC_4 327.83 − 11.83 0.56 − 3.57 0.17
JAGC_5 291.82 − 9.77 0.49 3.96 − 0.2
DPU_1 359.69 − 9.01 0.38 5.51 − 0.23
KP3 608.6 − 19.1 0.43 Nd nd
XMP 362.03 nd Nd − 82.17 3.42
Table 2.  ICM score for compounds JAGC_1-7 in the NAD+ and IMP binding sites of GuaB2. *nd = not 
determined, MWt = Molecular weight, LEI = Ligand Efficiency Index (ICM score/Number of heavy atoms), 
KP3 is the co-crystallised ligand in structure 4ZQP, XMP the product that occupies the IMP site in structure 
4ZQM.
Figure 2. An overlay of the in silico-derived binding orientations of all JAGC compounds, indicating that 
the compounds favour the NAD binding site of GuaB2. Their aromatic rings are positioned in the NAD+ 
nicotinamide sub-site close to the IMP and XMP binding sites.
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Figure 3. Binding orientations of compounds JAGC_7 and DPU-2 in the binding pocket of GuaB2.  
(A and B) Orientation of JAGC_7 (cyan) in the IMP site. Its 4-methyl cyclohexane ring occupies the xanthosine 
subsite and forms π -π stacking with the nicotinamide moiety of NAD+ and GuaB2-JAGC_7 interactions. 
Green sticks represent the NAD+ molecule. (C and D) Orientation of JAGC_7 in the NAD+ binding site where 
the 1,2,3,benzothiadiazole ring occupies the nicotinamide position and forms π -π bonds with IMP (brown 
sticks), and its interactions with binding site residues. (E and F) Binding orientation of DPU-2 (magenta) and its 
interactions of in the IMP binding site. The nitrophenyl moiety is positioned towards the nicotinamide scaffold 
of NAD+. (G and H) Binding orientation and interactions of DPU-2 in the NAD+ binding site. The nitrophenyl 
group is π stacking with the purin-6-one ring. In the interaction figures B, D, F and H, the red dotted lines 
represent hydrophobic interactions including π -π interactions between the inhibitor and the residues in the 
GuaB2 binding pockets and hydrogen bonds are shown by the dashed blue line.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:38986 | DOI: 10.1038/srep38986
in the NAD+ site where the aromatic benzothiadiazole ring, was placed in the nicotinamide site and was involved 
in π stacking with the purine ring in IMP (Fig. 3C). Stability of this conformation is also enhanced by hydrogen 
bonding to G184 and T343 whilst the cyclohexane ring is placed over the IMSM moiety. There are multiple 
hydrophobic interactions that due to π -π stacking between IMP and the 1,2,3-benzothiazol-5-yl rings (Fig. 3D).
In silico Binding Mode of DPU-2. The binding mode of the optimised DPU compound DPU-2, a known 
inhibitor of Mtb GuaB213, was similar to that of JAGC_7 and the rest of the compounds. When docked into the 
IMP site the nitrophenyl ring was placed in the xanthosine sub-site and there was π -π stacking with the nicotina-
mide ring in NAD+ (Fig. 3E) and hydrogen bonds to Met272 and Gly273 (Fig. 3F). The chlorophenyl ring occu-
pied the phosphate group sub-site and participated in π interactions with the hydrophobic residues like Gly223, 
L244, M243, π -π interactions with Tyr269, and hydrogen bonding to S56 through the Urea O atom and S187. 
However the binding scores in this site (ICM score = − 7.21, LEI = 0.34) showed that binding affinity was less than 
in the NAD+ site (ICM score = − 16.36, LEI = 0.78). In the NAD+ site the methyl nitrophenyl ring π stacked with 
the purine ring of IMP (Fig. 3G), resulting in multiple hydrophobic interactions, hydrogen bonding with Asp131 
and Thr191 in addition to a number of other hydrophobic contacts with the binding site residues (Fig. 3H).
Discussion
Until now, two opposing independent strategies have been favoured for TB drug discovery. The historical target 
to drug approach necessitates a formative detailed understanding of the selected target. This includes: (i) estab-
lishing the in vivo essentiality of the target, (ii) biochemical characterisation of the target and (iii) establishing 
the structures of the targets in complex with substrates and/or cofactors. Only then can inhibitory molecules be 
screened from compound libraries, designed de novo, discovered in silico, developed by fragment-based drug 
design, or rational drug design based upon cofactors or substrate chemical structure. Although compounds may 
show biochemical inhibition, they are unlikely to show whole-cell activity, and thus a target-to-drug approach 
is often considered a time consuming and costly drug discovery process. By contrast, a drug-to-target strategy 
generally involves a phenotypic screening method utilising whole-cells in order to establish potent inhibitors to 
cell growth and/or cell viability. This strategy has recently become the favoured approach in that it takes advantage 
of HTS to allow the screening of millions of compounds in a cost effective and timely manner. However, there 
remain limitations to this approach due to the biasing of compound libraries or the high propensity to identify 
compounds which target enzymes with highly susceptible binding sites, which may have homology to mamma-
lian enzymes and thus will limit the progression of a hit compound. As a result, there exists a demand for a drug 
discovery strategy, which combines the specificity of the target to drug approach with the broad reaching chemi-
cal potential of the drug to target approach (Fig. 4).
Here we have identified a series of novel compounds with activity against M. tuberculosis H37Rv. These 
hit compounds from the ‘TB Box’ set have been discovered by a phenotypic HTS campaign utilising constitu-
tive over-expression of a previously identified TB drug target, GuaB2, which was previously validated18. Upon 
over-expression of GuaB2, a resistance phenotype was observed that was not apparent in the empty vector control 
strain. Initial hit compounds have been verified in dose response and hits prioritised according to their pXC50 
shift data. Additionally, hits have also been validated as inhibitors in an in vitro Mtb GuaB2 biochemical assay.
Molecular docking approaches are widely applied in drug discovery and basic science to provide target-ligand 
complexes and hence information that facilitates structure-based drug discovery and molecular modification. 
The NAD+ binding site in GuaB2 stretches from the adenosine sub-site defined by N289, L291, V292 and G260 
to the nicotinamide sub-site with the middle part of the molecule stretching over the inhibitor minimal struc-
tural moiety (IMSM)19. Occupation of the nicotinamide sub-site and interactions of small molecules with the 
purine ring of IMP have been found to be crucial for binding and protein inhibition. In this site, the seven hit 
compounds JAGC_1–7 had had similar binding orientations to that of DPU-2. The observed activities of these 
compounds are attributed to a favourable positioning of molecular scaffolds in the binding site resulting in the 
important ligand-IMP interactions. For the hit compounds either an aromatic in JAGC_1–6 and DPU-2 or the 
hydrophobic cyclohexane ring in JAGC_7 occupied the nicotinamide sub-site, a position that favours π -π stack-
ing with the purine ring in IMP. A closer look at the GuaB2-JAGC_7 interactions reveals that the hydrophobic 
ring provides numerous interaction points to IMP (Fig. 3D), similarly to the nitrophenyl ring in DPU-2 and IMP 
interactions (Fig. 3H). The network of hydrophobic bonds coupled with hydrogen bonds stabilise the binding 
conformations of the ligands and result in high binding affinities. On the other hand, all hit compounds including 
DPU-2 displayed low affinities for buried IMP/XMP site irrespective of more hydrophobic and polar contacts 
(Fig. 3B and F) and similar binding orientations.
This new series of inhibitors, JAGC_1–7, together with the knowledge about their target and binding modes, 
provides a solid platform for future medicinal chemistry efforts to improve the activities of these scaffolds. 
Furthermore the identification of such a diverse collection of compounds gives credence to the incorporation of 
target-to-drug based strategies in high-throughput Mtb drug discovery.
Materials and Methods
Strains, transformation and culture. All experiments were performed in M. bovis BCG which has been 
transformed by a standard heat shock protocol with pMV261, a kanamycin-resistant mycobacterial over-ex-
presser plasmid, which had been modified by addition of Mtb guaB2. An empty vector strain (pMV261 only) was 
also prepared. Transformants were selected on Middlebrook 7H11 mycobacterial media (Difco) supplemented 
with 10% (v/v) OADC (oleic acid (1.25 × 10−2% v/v), albumin (1.25% w/v), dextrose (0.5% w/v) and catalase 
(1 × 10−3% w/v) (Sigma-Aldrich)), containing kanamycin at 25 μ g.ml−1. Successful transformants were trans-
ferred into Middlebrook 7H9 liquid media (Difco) containing kanamycin at 25 μ g.ml−1, 0.05% (v/v) Tween-80, 
0.25% (v/v) glycerol and supplemented with 10% (v/v) ADC (albumin (1.25% w/v), dextrose (0.5% w/v) and 
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catalase (7.5 × 10−4% w/v) (Sigma-Aldrich)). Growth rate was monitored by measuring optical density (OD) at 
600 nm and cells were passaged to maintain a mid-log OD600 of 0.4–0.8. To prevent mutagenesis, no more than 4 
passages were conducted before cultures were reinitiated from a glycerol stock.
High-throughput screening of over-expresser strains in single shot. The initial HTS was conducted 
in single shot, with 1536 well plates (32 rows × 48 columns) prepared with compounds at 1 and 0.1 mM (50 nl total 
compound volume). A liquid dispensing robot (MultidropTM Combi (Thermo Scientific)) was used to dispense 
5 μ l of a diluted mid-log culture (diluted to OD600 0.125 corresponding to 1 × 107 cfu.ml−1) into each well, so 
compounds were tested at 10 μ M and 1 μ M final assay concentration. A negative (DMSO only) control (control 1, 
column 11 and 12) and INH treated positive control (control 2, column 35 and 36) were also prepared on each 
plate. Plates were hermetically wrapped in aluminium foil with dummy plates at the top and bottom of each 
stack and incubated for 7 days at 37 °C in 5% CO2 with humidity. Following incubation, 5 μ l of reconstituted 
BacTiter-Glo™ was added to each well and the luminescence was measured using a Viewlux Reader (Perkin 
Elmer). The BacTiter-Glo™ assay causes cell lysis and allows the fluorimetric quantification of the amount of 
adenosine triphosphate (ATP) present in the reaction mix by an ATP-dependent thermostable luciferase lumines-
cent signal, which is directly proportional to the number of viable cells in the culture. This method was favoured 
over conventional Resazurin treatment as there is a lesser propensity for false positives. The effect of a given 
inhibitor was calculated as:
= × − −%inhibition 100 ((data control 1)/(control 2 control 1))
(where control 1 = maximum activity (DMSO only; uninhibited growth), and control 2 = bacterial growth com-
pletely inhibited (by treatment with 10 μ M isoniazid).
Assay performance statistics (signal to background ratio and Z′ ) were calculated using templates in 
ActivityBase XE (ID Bussines Solutions Ltd, Surrey, UK).
(The 256 compounds with the higher shift (calculated as % Inhibition in Empty vector strain - % Inhibition in 
over-expresser strain) from each strain tested were selected to be tested in dose response.)
Dose response validation of hits. Hits identified in the single shot HTS were investigated further by 
conducting a dose response experiment following the same 1536 well format and experimental conditions as 
described above. The only difference in method is that hit compounds were plated in serial dilution of 11 steps 
from 10 mM to 0.17 nM using a 1/3 dilution factor all in a 50 nl total volume. The controls as described above were 
repeated for each plate and data was obtained in duplicate.
Figure 4. A change in strategy for Mtb drug discovery. Recent innovations in screening technologies 
and robotics have heralded a change in strategy for primary antimicrobial drug discovery. Efforts to design 
inhibitors of specific bacterial targets as potential drugs (Target to Drug) have given way to the screening of 
substantial compound libraries for whole cell activity and subsequent target identification (Drug to Target). 
The former strategy lacks efficacy, as biochemical inhibitory activity does not necessarily translate to whole cell 
inhibitory activity. The latter, produces a vast array of antimicrobial compounds, however their mode of action 
is often not conducive to their progression as clinically relevant drugs. Here we have employed a combined 
strategy, screening for phenotypic resistance caused by over-expression of a mycobacteria-specific drug target, 
GuaB2, in M. bovis BCG. The outputs of this approach are compounds with confirmed whole cell activity and 
with a mode of action conducive to further development from compounds to drugs.
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Data analysis. The % Inhibition for each compound concentration tested were calculated as described above. 
Dose response curves for each of the compounds were analyzed using the ActivityBase XE template (ID Business 
Solutions Ltd, Surrey, UK). pXC50 values were obtained using the ActivityBase XE nonlinear regression function 
in the full curve analysis bundle.
Biochemical Assay of GuaB2 Inhibition. The Mtb ortholog of the enzyme was recombinantly expressed, 
purified and assayed as previously described18. Inhibition was determined at 0.1 mM, using 12 μ g GuaB2 with the 
addition of 0.5% CHAPS. Each assay was normalised for DMSO concentration. Data was recorded in duplicate 
and analysed using Graphpad Prism 6.0.
In silico molecular docking of Compounds JAGC_1–7. The Internal Coordinate Mechanism (ICM) 
method developed by Molsoft L.L.C25 was used to generate binding modes of the 9 small molecules in the binding 
pocket of selected GuaB2 crystal structures from the PDB and to estimate the strength of the protein-ligand inter-
actions based on the ICM scoring function. The scoring function is defined as the sum of energy changes when 
the ligand binds to the protein, given as:
α∆ = ∆ + ∆ + α ∆ + α ∆ + α ∆ + α ∆ +G E T S E E E E QIntFF Tor 1 HBond 2 HBDesol 3 SolEl 4 HPhob 5 Size
where Δ EIntFF, is the change in van der Waals interactions of ligand and receptor and the internal force-field 
energy of the ligand, TΔ STor, is the change in free energy due to conformational entropy and weighted (α 1 − α 5), 
Δ EHBond is the hydrogen bond term,
Δ EHBDesol accounts for the disruption of hydrogen bonds with solvent, Δ ESolEl is the solvation electrostatic 
energy change upon binding, Δ EHPhob is the hydrophobic free energy gain and Qsize is the ligand size correction 
term. The ICM scores were standardized by calculating the ligand efficiency indices (LEI) as a ratio of the ICM 
score to the number of heavy atoms in the ligand for each docked molecule26.
In silico protein structure preparation. A number of structures of GuaB2 have been deposited into the 
PDBe and four of these have GuaB2 co-crystallised with substrate, NAD+ and product, XMP (PDB code: 4zqm), 
and with IMP and antitubercular compounds (PDB codes: 4zqp, 4zqo and 4zqn). The structures reveal that 
NAD+ and XMP occupy different binding sites19 and the antitubercular compounds bind to the NAD+ pocket 
whilst IMP occupies the XMP site. The NAD+ site is an exposed open pocket defined by the residues N289, L291, 
V292, G260, T284, A285 and D283. This pocket extends into a tunnel-like pocket that forms part of the IMP 
binding site made up of residues like T343, G334, E458, N313, D374. We extracted the four crystal structures 
from the PBDe to use in our docking calculations. To validate our calculations, firstly, the coordinates of the 
ligands occupying the NAD+ pocket (akp3, a4qo, aq67 and NAD+) were removed from their respective structure 
files (Table 2) and were saved into separate files. Using ICM-docking receptor preparation tools the four protein 
structures were separately prepared by deleting all water molecules, optimize hydrogen, adding missing heavy 
atoms and hydrogen, and adjusting amide groups and were saved as ICM receptor molecules. The “setup recep-
tor” tool was used to generate receptor maps using a grid size of 0.5 Å, and over binding sites consisting of 19 to 
28 residues in protein structures (Table 2). Secondly, after extracting XMP from the 4ZQM structure, grid maps 
were generated over its binding site defined by 31 residues (Table 3). Overlaying their Cα atoms, calculating the 
root mean square deviations and analysing the residue side chain orientations in the binding pockets evaluated 
the differences between the 4 GuaB2 structures.
Validation of docking calculations. The ligand structures were similarly prepared and converted to ICM 
molecules with the corrected bond order and stereochemistry. Cross-docking was used to assist with identifying 
the GuaB2 conformation and parameters to use during the production stage and to validate the docking calcu-
lations. Cross-docking involved docking each prepared ligands structures into the NAD+ binding pocket in all 
four GuaB2 conformations, including re-docking ligands into their respective protein structures and optimising 
the parameters. The generated binding conformations were compared to the crystal structure conformations. 
It was observed that the GuaB2 structure, PDB code: 4ZQP, was able to regenerate the crystal conformations of 
all ligands with root mean square deviations (RMSD) ranging from 0.94 to 2.00, indicating its versatility. Hence 
docking calculations using 4ZQP were repeated to optimise the docking parameters and the docking thorough-
ness/effort was set to 5. Similarly, the ligand XMP was re-docked into its binding pocket in structure 4ZQM and 
the docking parameters were optimised and thoroughness/effort was set to 2.
PDBe Structure Code Ligand Code
Number of Binding 
site residues
Grid dimensions 
(X,Y,Z) (Å) Grid size (Å)
4ZQP KP3 28 16.31,18.39,15.64 0.5
4ZQO Q67 19 23.43,21.81,23.89 0.5
4ZQM NAD+ 31 12.62,13.56,12.07 0.5
4ZQM XMP 31 17.43,16.50,20.70 0.5
4ZQN 4ZQO 24 21.83,23.07,22.46 0.5
Table 3.  Ligands and Grid properties for GuaB2 structures.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:38986 | DOI: 10.1038/srep38986
In silico ligand preparation and docking. Three dimension coordinates of 9 compounds, including 
diphenyl urea, DPU-2, known to inhibit GuaB2, were generated using a Pipeline Pilot protocol and saved as mol2 
files. The molecules were imported into ICMdock, amide bonds were fixed, hydrogen atoms were built and the 
structures were converted and saved as ICM compatible molecules. The compounds were first docked into the 
NAD+ binding pocket of 4ZPQ using thoroughness/effort value of 5 and default ICM parameters. To determine 
occupancy of the ligands in the large binding pocket, the compounds were re-docked into the XMP binding 
pocket in 4QZM. The best ICM scoring conformation for each compound was extracted and their ligand effi-
ciency indices (LEI)26 were calculated dividing each ICM score by the number of heavy atoms in the molecules.
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